Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 306

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 306
---
 by such person and the exercise price (as applicable), date of grant, vesting schedule and expiry date of each such Incentive Security, as well as 
 a true and complete copy of the Equity Incentive Plan and the Option Plan.                                                                                                                                                                               |

| (b) | All outstanding Common Shares and the Common Shares to be issued on the exercise or settlement of Incentive                                                                                                                                               
 Securities and the Warrant have been duly authorized. The outstanding Common Shares are, and the Common Shares to be issued on the exercise of Incentive Securities and the Warrant will be when issued, validly issued and outstanding as fully paid and 
 non-assessable shares.                                                                                                                                                                                                                                    |

| (c) | Except as set forth in Schedule 2(c) to the Disclosure Letter, there are no outstanding bonds, debentures or                                                                                                                                             
 other evidence of indebtedness of the Company or any Subsidiary of the Company having the right to vote (or that are convertible for or exercisable into securities having the right to vote) with the holders of the Common Shares on any matter. There 
 are no outstanding obligations of the Company or any Subsidiary of the Company to repurchase, redeem or otherwise acquire any outstanding Common Shares or with respect to the voting or disposition of any outstanding securities of the Company or any 
 Subsidiary of the Company.                                                                                                                                                                                                                               |

| (d) | Except as set forth in Schedule 2(d) to the Disclosure Letter, no holder of securities issued by the Company or                                                          
 any Subsidiary of the Company has any right to compel the Company to register or otherwise qualify securities for public sale in Canada, the United States or elsewhere. |

| (e) | The rights, privileges, restrictions and conditions attached to the Common Shares of the Company are as set out 
 in the articles of incorporation of the Company together with any amendments thereto or replacements thereof.   |

| (f) | Except as set out in Schedule 2(f) to the Disclosure Letter, no Shareholder has any existing participation                                    
 right or pre-emptive right or right of first refusal in respect of the allotment and issuance of any unissued or other shares of the Company. |

A-69

| 3. | Authority |

The Company has the requisite power and authority to enter into this Agreement and to perform its obligations hereunder. This Agreement has been duly authorized, executed and delivered by the Company and is a valid and binding agreement of the Company enforceable against